Current and emerging tests for the laboratory monitoring of chronic myeloid leukaemia and related disorders

Pathology

Volumn 40, Issue 3, 2008, Pages 231-246

  Ross, D M ^a   Hughes, T P ^a  

^a INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

Author keywords

Chronic myeloid leukaemia; Haematology; Leukaemia; Monitoring; Treatment

Indexed keywords

ABELSON KINASE; ALPHA INTERFERON; BCR ABL PROTEIN; CGP 074588; CYTARABINE; DASATINIB; DRUG METABOLITE; IMATINIB; INTERFERON; NILOTINIB; NORIMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ADVANCED CANCER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SUSCEPTIBILITY; CANCER THERAPY; CHEMOSENSITIVITY; CHROMOSOME 9; CHRONIC MYELOID LEUKEMIA; CLINICAL ASSESSMENT; CLINICAL TRIAL; CYTOGENETICS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EXPOSURE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG UPTAKE; DRUG WITHDRAWAL; EFFUSION; EOSINOPHILIC LEUKEMIA; FUSION GENE; GENE DELETION; GENE MUTATION; GENETIC ASSOCIATION; HEMATOLOGICAL PARAMETERS; HUMAN; HYPEREOSINOPHILIC SYNDROME; IC 50; IMMUNOPHENOTYPING; INTRACELLULAR SPACE; KARYOTYPE; LABORATORY TEST; LEUKEMIA; LEUKEMIA CELL; LEUKEMOGENESIS; MOLECULAR DYNAMICS; MYELOPROLIFERATIVE DISORDER; NONHUMAN; ONCOGENE; POINT MUTATION; PROGNOSIS; PROTEIN DOMAIN; QUALITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SCORING SYSTEM; TREATMENT RESPONSE;

EID: 42449109009     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1080/00313020801916172     Document Type: Article

References (195)

1. Hughes T, Branford S. Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia. Blood Rev 2006; 20: 29-41.
2. Branford S, Hughes T. Diagnosis and monitoring of chronic myeloid leukemia by qualitative and quantitative RT-PCR. Methods Mol Med 2006; 125: 69-92.
3. Ross DM, Hughes TP. Cancer treatment with kinase inhibitors: what have we learnt from imatinib? Br J Cancer 2004; 90: 12-9.
4. Rowley JD. Identification of a translocation with quinacrine fluorescence in a patient with acute leukemia. Ann Genet 1973; 16: 109-12.
5. Nowell P, Hungerford D. A minute chromosome in human chronic granulocytic leukemia. Science 1960; 132: 1497-501.
6. Heisterkamp N, Stam K, Groffen J, de Klein A, Grosveld G. Structural organization of the bcr gene and its role in the Ph' translocation. Nature 1985; 315: 758-61.
7. Groffen J, Stephenson JR, Heisterkamp N, et al. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984; 36: 93-9.
8. Laurent E, Talpaz M, Kantarjian H, Kurzrock R. The BCR gene and philadelphia chromosome-positive leukemogenesis. Cancer Res 2001; 61: 2343-55.
9. Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 1996; 88: 2375-84.
10. Van Etten RA. Cycling, stressed-out and nervous: cellular functions of c-Abl. Trends Cell Biol 1999; 9: 179-86.
11. Taagepera S, McDonald D, Loeb JE, et al. Nuclear-cytoplasmic shuttling of C-ABL tyrosine kinase. Proc Natl Acad Sci USA 1998; 95: 7457-62.
12. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000; 96: 3343-56.
13. Kantarjian HM, Dixon D, Keating MJ, et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 1988; 61: 1441-6.
14. Guilhot F, Roy L, Guilhot J, Millot F. Interferon therapy in chronic myelogenous leukemia. Hematol Oncol Clin North Am 2004; 18: 585-603, viii.
15. Jaffe E, Harris N, Stein H, Vardiman J, editors. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoeitic and Lymphoid Tissues. Lyon: IARC Press, 2001.
16. Kantarjian HM, Keating MJ, Estey EH, et al. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine. J Clin Oncol 1992; 10: 772-8.
17. Kantarjian H, Talpaz M, O'Brien S, et al. Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia - comparison with historic experience. Cancer 2005; 103: 2099-108.
18. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99: 1928-37.
19. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354: 2542-51.
20. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354: 2531-41.
21. Cortes J, Rousselot P, Kim DW, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007; 109: 3207-13.
22. Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996; 56: 100-4.
23. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561-6.
24. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004.
25. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408-17.
26. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 1423-32.
27. Guilhot F, Druker BJ, O'Brien SG, Larson RA. Cytogenetic response and discontinuations from IRIS study with long term imatinib therapy (IM) in newly diagnosed Ph+ chronic myelogenous leukemia (Ph+CML). Haematologica 2007; 92: (Abstr 357).
28. Gratwohl A, Brand R, Apperley J, et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006:transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006; 91: 513-21.
29. Hehlmann R, Berger U, Pfirrmann M, et al. Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood 2007; 109: 4686-92.
30. Catovsky D. Leucocyte cytochemical and immunological techniques. In: Dacie JV, Lewis SM, editors. Practical Haematology. 8th ed. Edinburgh: Churchill Livingstone, 1995; 143-74.
31. Allan NC, Shepherd PC. Treatment of chronic myeloid leukaemia. Baillieres Clin Haematol 1987; 1: 1031-54.
32. Ottmann OG, Druker BJ, Sawyers CL, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002; 100: 1965-71.
33. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99: 3530-9.
34. Saikia T, Advani S, Dasgupta A, et al. Characterisation of blast cells during blastic phase of chronic myeloid leukaemia by immunophenotyping- experience in 60 patients. Leuk Res 1988; 12: 499-506.
35. Khalidi HS, Brynes RK, Medeiros LJ, et al. The immunophenotype of blast transformation of chronic myelogenous leukemia: a high frequency of mixed lineage phenotype in 'lymphoid' blasts and a comparison of morphologic, immunophenotypic, and molecular findings. Mod Pathol 1998; 11: 1211-21.
36. Tabernero MD, Bortoluci AM, Alaejos I, et al. Adult precursor BALL with BCR/ABL gene rearrangements displays a unique immunophenotype based on the pattern of CD10, CD34, CD13 and CD38 expresssion. Leukemia 2001; 15: 406-14.
37. Martin-Henao GA, Quiroga R, Sureda A, Garcia J. CD7 expression on CD34+ cells from chronic myeloid leukaemia in chronic phase. Am J Hematol 1999; 61: 178-86.
38. Normann AP, Egeland T, Madshus IH, Heim S, Tjonnfjord GE. CD7 expression by CD34+ cells in CML patients, of prognostic significance? Eur J Haematol 2003; 71: 266-75.
39. Yong AS, Szydlo RM, Goldman JM, Apperley JF, Melo JV. Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML. Blood 2006; 107: 205-12.
40. Kosugi N, Ebihara Y, Nakahata T, et al. CD34+CD7+ leukemic progenitor cells may be involved in maintenance and clonal evolution of chronic myeloid leukemia. Clin Cancer Res 2005; 11: 505-11.
41. El-Zimaity MM, Kantarjian H, Talpaz M, et al. Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome. Br J Haematol 2004; 125: 187-95.
42. Huntly BJ, Reid AG, Bench AJ, et al. Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood 2001; 98: 1732-8.
43. Kantarjian HM, Smith TL, McCredie KB, et al. Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival. Blood 1985; 66: 1326-35.
44. Sokal JE, Gomez GA, Baccarani M, et al. Prognostic significance of additional cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive chronic granulocytic leukemia. Blood 1988; 72: 294-8.
45. Farag SS, Ruppert AS, Mrozek K, et al. Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha: a Cancer and Leukemia Group B study. Int J Oncol 2004; 25: 143-51.
46. Wu Y, Slovak ML, Snyder DS, Arber DA. Coexistence of inversion 16 and the Philadelphia chromosome in acute and chronic myeloid leukemias: report of six cases and review of literature. Am J Clin Pathol 2006; 125: 260-6.
47. Nakase K, Yamamoto Y, Morita K, et al. Haunting appearance of bcr/abl fusion gene products in a patient with therapy related leukaemia. Leuk Res 2006; 30: 106-8.
48. Soupir CP, Vergilio JA, Dal Cin P, et al. Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis. Am J Clin Pathol 2007; 127: 642-50.
49. Keung YK, Beaty M, Powell BL, et al. Philadelphia chromosome positive myelodysplastic syndrome and acute myeloid leukemia-retrospective study and review of literature. Leuk Res 2004; 28: 579-86.
50. Paietta E, Racevskis J, Bennett JM, et al. Biologic heterogeneity in Philadelphia chromosome-positive acute leukemia with myeloid morphology: the Eastern Cooperative Oncology Group experience. Leukemia 1998; 12: 1881-5.
51. Branford S, Hughes TP. Diagnosis and monitoring of chronic myeloid leukemia by qualitative and quantitative RT-PCR. In: Iland HJ, Hertzberg M, Marlton P, editors. Myeloid leukemia: Methods and Protocols, Methods in Molecular Medicine. Totawa, NJ: Humana Press, 2006; 69-92.
52. de la Fuente J, Merx K, Steer EJ, et al. ABL-BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemia. Blood 2001; 98: 2879-80.
53. Rozman C, Urbano-Ispizua A, Cervantes F, et al. Analysis of the clinical relevance of the breakpoint location within M-BCR and the type of chimeric mRNA in chronic myelogenous leukemia. Leukemia 1995; 9: 1104-7.
54. Shepherd P, Suffolk R, Halsey J, Allan N. Analysis of molecular breakpoint and m-RNA transcripts in a prospective randomized trial of interferon in chronic myeloid leukaemia: no correlation with clinical features, cytogenetic response, duration of chronic phase, or survival. Br J Haematol 1995; 89: 546-54.
55. Saussele S, Weisser A, Muller MC, et al. Frequent polymorphism in BCR exon b2 identified in BCR-ABL positive and negative individuals using fluorescent hybridization probes. Leukemia 2000; 14: 2006-10.
56. Branford S, Hughes TP, Rudzki Z. Dual transcription of b2a2 and b3a2 BCR-ABL transcripts in chronic myeloid leukaemia is confined to patients with a linked polymorphism within the BCR gene. Br J Haematol 2002; 117: 875-7.
57. Morris SW, Daniel L, Ahmed CM, Elias A, Lebowitz P. Relationship of bcr breakpoint to chronic phase duration, survival, and blast crisis lineage in chronic myelogenous leukemia patients presenting in early chronic phase. Blood 1990; 75: 2035-41.
58. Ravandi F, Cortes J, Albitar M, et al. Chronic myelogenous leukaemia with p185(BCR/ABL) expression: characteristics and clinical significance. Br J Haematol 1999; 107: 581-6.
59. Melo JV, Myint H, Galton DA, Goldman JM. P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia? Leukemia 1994; 8: 208-11.
60. Lichty BD, Keating A, Callum J, et al. Expression of p210 and p190 BCR-ABL due to alternative splicing in chronic myelogenous leukaemia. Br J Haematol 1998; 103: 711-5.
61. van Rhee F, Hochhaus A, Lin F, et al. p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias. Blood 1996; 87: 5213-7.
62. Voncken JW, Kaartinen V, Pattengale PK, et al. BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice. Blood 1995; 86: 4603-11.
63. Li S, Ilaria RL Jr, Million RP, Daley GQ, Van Etten RA. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med 1999; 189: 1399-412.
64. Pane F, Intrieri M, Quintarelli C, et al. BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical correlations. Oncogene 2002; 21: 8652-67.
65. Lee JJ, Kim HJ, Kim YJ, et al. Imatinib induces a cytogenetic response in blast crisis or interferon failure chronic myeloid leukemia patients with e19a2 BCR-ABL transcripts. Leukemia 2004; 18: 1539-40.
66. Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 1998; 92: 3362-7.
67. Biernaux C, Loos M, Sels A, Huez G, Stryckmans P. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 1995; 86: 3118-22.
68. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 2002; 359: 1577-8.
69. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348: 1201-14.
70. Metzgeroth G, Walz C, Score J, et al. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia 2007; 21: 1183-8.
71. Jovanovic JV, Score J, Waghorn K, et al. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 2007; 109: 4635-40.
72. von Bubnoff N, Sandherr M, Schlimok G, et al. Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia. Leukemia 2005; 19: 286-7.
73. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876-80.
74. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994; 77: 307-16.
75. Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002; 347: 481-7.
76. David M, Cross NC, Burgstaller S, et al. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood 2007; 109: 61-4.
77. Baxter EJ, Hochhaus A, Bolufer P, et al. The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. Hum Mol Genet 2002; 11: 1391-7.
78. Griesinger F, Hennig H, Hillmer F, et al. A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia. Genes Chromosomes Cancer 2005; 44: 329-33.
79. Demiroglu A, Steer EJ, Heath C, et al. The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1:transforming activity and specific inhibition of FGFR1 fusion proteins. Blood 2001; 98: 3778-83.
80. Papadopoulos P, Ridge SA, Boucher CA, Stocking C, Wiedemann LM. The novel activation of ABL by fusion to an ets-related gene, TEL. Cancer Res 1995; 55: 34-8.
81. Pardanani A, Hood J, Lasho T, et al. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia 2007; 21: 1658-68.
82. Kuenen BC, Giaccone G, Ruijter R, et al. Dose-finding study of the multitargeted tyrosine kinase inhibitor SU6668 in patients with advanced malignancies. Clin Cancer Res 2005; 11: 6240-6.
83. Irish JM, Hovland R, Krutzik PO, et al. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell 2004; 118: 217-28.
84. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in 'good-risk' chronic granulocytic leukemia. Blood 1984; 63: 789-99.
85. Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998; 90: 850-8.
86. Dewald GW, Wyatt WA, Silver RT. Atypical BCR and ABL D-FISH patterns in chronic myeloid leukemia and their possible role in therapy. Leuk Lymphoma 1999; 34: 481-91.
87. Sinclair PB, Nacheva EP, Leversha M, et al. Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood 2000; 95: 738-43.
88. Herens C, Tassin F, Lemaire V, et al. Deletion of the 5′-ABL region: a recurrent anomaly detected by fluorescence in situ hybridization in about 10% of Philadelphia-positive chronic myeloid leukaemia patients. Br J Haematol 2000; 110: 214-6.
89. Quintas-Cardama A, Kantarjian H, Talpaz M, et al. Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood 2005; 105: 2281-6.
90. Kolomietz E, Al-Maghrabi J, Brennan S, et al. Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis. Blood 2001; 97: 3581-8.
91. Cohen N, Rozenfeld-Granot G, Hardan I, et al. Subgroup of patients with Philadelphia-positive chronic myelogenous leukemia characterized by a deletion of 9q proximal to ABL gene: expression profiling, resistance to interferon therapy, and poor prognosis. Cancer Genet Cytogenet 2001; 128: 114-9.
92. Rudduck-Sivaswaren C, Tien SL, Lim P, et al. Evidence for deletion of 9q as a two-step process in chronic myeloid leukemia. Clin Genet 2005; 68: 461-5.
93. Xinh PT, Vu HA, Nghia H, et al. Coexistence of Philadelphia chromosome positive cells with and without der(9) deletion in a patient with chronic myelogenous leukemia. Cancer Genet Cytogenet 2006; 164: 122-7.
94. Yoong Y, VanDeWalker TJ, Carlson RO, Dewald GW, Tefferi A. Clinical correlates of submicroscopic deletions involving the ABL-BCR translocation region in chronic myeloid leukemia. Eur J Haematol 2005; 74: 124-7.
95. Kreil S, Pfirrmann M, Haferlach C, et al. Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia. Blood 2007; 110: 1283-90.
96. Huntly BJ, Guilhot F, Reid AG, et al. Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. Blood 2003; 102: 2205-12.
97. Rego EM, Pandolfi PP. Reciprocal products of chromosomal translocations in human cancer pathogenesis: key players or innocent bystanders? Trends Mol Med 2002; 8: 396-405.
98. Melo JV, Gordon DE, Cross NC, Goldman JM. The ABL-BCR fusion gene is expressed in chronic myeloid leukemia. Blood 1993; 81: 158-65.
99. Melo JV, Hochhaus A, Yan XH, Goldman JM. Lack of correlation between ABL-BCR expression and response to interferon-alpha in chronic myeloid leukaemia. Br J Haematol 1996; 92: 684-6.
100. Huntly BJ, Bench A, Green AR. Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia. Blood 2003; 102: 1160-8.
101. Nowicki MO, Falinski R, Koptyra M, et al. BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. Blood 2004; 104: 3746-53.
102. Koptyra M, Falinski R, Nowicki MO, et al. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood 2006; 108: 319-27.
103. Neumann F, Teutsch N, Kliszewski S, et al. Gene expression profiling of Philadelphia chromosome (Ph)-negativeCD34+ hematopoietic stem and progenitor cells of patients with Ph-positive CML in major molecular remission during therapy with imatinib. Leukemia 2005; 19: 458-60.
104. Oda T, Heaney C, Hagopian JR, et al. Crkl is the major tyrosinephosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J Biol Chem 1994; 269: 22925-8.
105. ten Hoeve J, Arlinghaus RB, Guo JQ, Heisterkamp N, Groffen J. Tyrosine phosphorylation of CRKL in Philadelphia+ leukemia. Blood 1994; 84: 1731-6.
106. Hamilton A, Elrick L, Myssina S, et al. BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry. Leukemia 2006; 20: 1035-9.
107. White DL, Saunders VA, Dang P, et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 Activity. Higher doses of imatinib may overcome the negative impact of low OCT-1 Activity. Blood 2007; 110: 4064-72.
108. Hughes T, Branford S, Matthews J, et al. Trial of higher-dose imatinib with selective intensification in newly diagnosed CML patients in the chronic phase. Blood 2003; 102: 31a (Abstr 95).
109. Hughes T, Branford S, Reynolds J, et al. Higher-dose imatinib (600 mg/day) with selective intensification in newly diagnosed CML patients in chronic phase; cytogenetic response rates at 12 months are superior to IRIS. Blood 2004; 104: 286a (Abstr 1001).
110. Haiat S, Decleves X, Mittaine B, et al. Determination of imatinib plasma levels by high performance liquid chromatography (HPLC): evaluation of pharmacokinetic variability and haematological consequences. Blood 2006; 108: 401a (Abstr).
111. White D, Saunders V, Lyons AB, et al. In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. Blood 2005; 106: 2520-6.
112. Wang L, Giannoudis A, Lane S, et al. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 2007; Jun 13: e-pub ahead of print.
113. White DL, Saunders VA, Dang P, et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006; 108: 697-704.
114. Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004; 104: 3739-45.
115. Illmer T, Schaich M, Platzbecker U, et al. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 2004; 18: 401-8.
116. Rumpold H, Wolf AM, Gruenewald K, et al. RNAi-mediated knockdown of P-glycoprotein using a transposon-based vector system durably restores imatinib sensitivity in imatinib-resistant CML cell lines. Exp Hematol 2005; 33: 767-75.
117. Mahon FX, Belloc F, Lagarde V, et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003; 101: 2368-73.
118. Jiang X, Zhao Y, Smith C, et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 2007; 21: 926-35.
119. White D, Dang P, Venables A, et al. ABCB1 overexpression may predispose imatinib treated CML patients to the development of Abl kinase domain mutations, and may be an important contributor to acquired resistance. Blood 2006; 108: 608a.
120. Cavalcanti GB Jr, da Cunha Vasconcelos F, Pinto de Faria G, et al. Coexpression of p53 protein and MDR functional phenotype in leukemias: the predominant association in chronic myeloid leukemia. Cytometry B Clin Cytom 2004; 61: 1-8.
121. Doyle LA, Ross DD. Multidrug resistance-mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003; 22: 7340-58.
122. Jordanides NE, Jorgensen HG, Holyoake TL, Mountford JC. Functional ABCG2 is over-expressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. Blood 2006; 108: 1370-3.
123. Houghton PJ, Germain GS, Harwood FC, et al. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res 2004; 64: 2333-7.
124. Kuppens IE, Breedveld P, Beijnen JH, Schellens JH. Modulation of oral drug bioavailability: from preclinical mechanism to therapeutic application. Cancer Invest 2005; 23: 443-64.
125. Breedveld P, Pluim D, Cipriani G, et al. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res 2005; 65: 2577-82.
126. Gardner ER, Burger H, van Schaik RH, et al. Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Clin Pharmacol Ther 2006; 80: 192-201.
127. White DL, Saunders VA, Quinn SR, Manley PW, Hughes TP. Imatinib increases the intracellular concentration of nilotinib, which may explain the observed synergy between these drugs. Blood 2007; 109: 3609-10.
128. Kamath AV, Wang J, Lee FY, Marathe PH. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. Cancer Chemother Pharmacol 2007; 61: 365-76.
129. Brendel C, Scharenberg C, Dohse M, et al. Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia 2007; 21: 1267-75.
130. Guilhot F, Chastang C, Michallet M, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med 1997; 337: 223-9.
131. Rosti G, Testoni N, Martinelli G, Baccarani M. The cytogenetic response as a surrogate marker of survival. Semin Hematol 2003; 40: 56-61.
132. Anastasi J, Feng J, Le Beau MM, et al. The relationship between secondary chromosomal abnormalities and blast transformation in chronic myelogenous leukemia. Leukemia 1995; 9: 628-33.
133. Marktel S, Marin D, Foot N, et al. Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression. Haematologica 2003; 88: 260-7.
134. O'Dwyer ME, Mauro MJ, Blasdel C, et al. Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate. Blood 2004; 103: 451-5.
135. Cortes JE, Talpaz M, Giles F, et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood 2003; 101: 3794-800.
136. O'Dwyer ME, Mauro MJ, Kurilik G, et al. The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood 2002; 100: 1628-33.
137. Bain BJ. Bone marrow biopsy morbidity and mortality: 2002 data. Clin Lab Haematol 2004; 26: 315-8.
138. Eikelboom JW. Bone marrow biopsy in thrombocytopenic or anticoagulated patients. Br J Haematol 2005; 129: 562-3.
139. Branford S, Hughes TP, Rudzki Z. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br J Haematol 1999; 107: 587-99.
140. Lange T, Bumm T, Otto S, et al. Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics formonitoring patientswith chronicmyeloid leukemia during early phase of imatinib therapy. Haematologica 2004; 89: 49-57.
141. Cuneo A, Bigoni R, Emmanuel B, et al. Fluorescence in situ hybridization for the detection and monitoring of the Ph-positive clone in chronic myelogenous leukemia: comparison with metaphase banding analysis. Leukemia 1998; 12: 1718-23.
142. Kovitz C, Kantarjian H, Garcia-Manero G, Abruzzo LV, Cortes J. Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. Blood 2006; 108: 2811-3.
143. Medina J, Kantarjian H, Talpaz M, et al. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer 2003; 98: 1905-11.
144. O'Dwyer ME, Gatter KM, Loriaux M, et al. Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. Leukemia 2003; 17: 481-7.
145. Terre C, Eclache V, Rousselot P, et al. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia 2004; 18: 1340-6.
146. Roy L, Guilhot J, Martineau G, Larchee R, Guilhot F. Unexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemia. Leukemia 2005; 19: 1689-92.
147. Ross DM, Branford S, Moore S, Hughes TP. Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL. Leukemia 2006; 20: 664-70.
148. Ross DM, Jackson SR, Browett PJ. Philadelphia-negative secondary acute myeloid leukaemia during imatinib treatment for chronic phase chronic myeloid leukaemia. Leuk Lymphoma 2007; 48: 1231-3.
149. Herens C, Baron F, Croisiau C, Tassin F, Bours V. Clonal chromosome aberrations in Philadelphia-negative cells from chronic myelocytic leukemia patients treated with imatinib mesylate: report of two cases. Cancer Genet Cytogenet 2003; 147: 78-80.
150. Wang L, Pearson K, Pillitteri L, Ferguson JE, Clark RE. Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia. Br J Haematol 2002; 118: 771-7.
151. Merx K, Muller MC, Kreil S, et al. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. Leukemia 2002; 16: 1579-83.
152. Cortes J, O'Dwyer ME. Clonal evolution in chronic myelogenous leukemia. Hematol Oncol Clin North Am 2004; 18: 671-84, x.
153. van der Velden VH, Boeckx N, Gonzalez M, et al. Differential stability of control gene and fusion gene transcripts over time may hamper accurate quantification of minimal residual disease - a study within the Europe Against Cancer Program. Leukemia 2004; 18: 884-6.
154. Beillard E, Pallisgaard N, van der Velden VH, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia 2003; 17: 2474-86.
155. Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 2003; 17: 2318-57.
156. Branford S, Cross NC, Hochhaus A, et al. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia 2006; 20: 1925-30.
157. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1: 307-10.
158. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108: 28-37.
159. Branford S, Fletcher L, Cross NCP, et al. Validation of the international scale for measurement of BCR-ABL by RQ-PCR based on deriving laboratory-specific conversion factors. Blood (in press).
160. Cross NC, Hughes TP, Hochhaus A, Goldman JM. International standardisation of quantitative real-time RT-PCR for BCR-ABL. Leuk Res 2007; May 17: e-pub ahead of print.
161. Branford S, Seymour J, Grigg A, et al. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clin Cancer Res 2007; 13: 780-5.
162. Mughal TI, Yong A, Szydlo RM, et al. Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse. Br J Haematol 2001; 115: 569-74.
163. Lange T, Bumm T, Mueller M, et al. Durability of molecular remission in chronic myeloid leukemia patients treated with imatinib vs allogeneic stem cell transplantation. Leukemia 2005; 19: 1262-5.
164. Radich JP, Gehly G, Gooley T, et al. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood 1995; 85: 2632-8.
165. Mauro MJ, Druker BJ, Maziarz RT. Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. Leuk Res 2004; 28 (Suppl 1): S71-3.
166. Cortes J, O'Brien S, Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood 2004; 104: 2204-5.
167. Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007; 109: 58-60.
168. Ross DM, Bartley PA, Morley AA, et al. Detection of patient-specific BCR-ABL genomic DNA in CML patients with no detectable BCR-ABL by quantitative reverse transcriptase PCR. Haematologica 2007; 92: (Abstr 567).
169. Thorn I, Olsson-Stromberg U, Ohlsen C, et al. The impact of RNA stabilization on minimal residual disease assessment in chronic myeloid leukemia. Haematologica 2005; 90: 1471-6.
170. Branford S, Rudzki Z, Walsh S, et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Phpositive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002; 99: 3472-5.
171. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2: 117-25.
172. Al-Ali HK, Heinrich MC, Lange T, et al. High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. Hematol J 2004; 5: 55-60.
173. Branford S, Rudzki Z, Parkinson I, et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood 2004; 104: 2926-32.
174. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002; 100: 1014-8.
175. Willis SG, Lange T, Demehri S, et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005; 106: 2128-37.
176. Miething C, Feihl S, Mugler C, et al. The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib. Leukemia 2006; 20: 650-7.
177. Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003; 102: 276-83.
178. Soverini S, Colarossi S, Gnani A, et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 2006; 12: 7374-9.
179. Nicolini FE, Corm S, Le QH, et al. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP). Leukemia 2006; 20: 1061-6.
180. Soverini S, Martinelli G, Rosti G, et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 2005; 23: 4100-9.
181. Jabbour E, Kantarjian H, Jones D, et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 2006; 20: 1767-73.
182. Griswold IJ, MacPartlin M, Bumm T, et al. Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol Cell Biol 2006; 26: 6082-93.
183. Ray A, Cowan-Jacob SW, Manley PW, Mestan J, Griffin JD. Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. Blood 2007; 109: 5011-5.
184. Bradeen HA, Eide CA, O'Hare T, et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an Nethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 2006; 108: 2332-8.
185. O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005; 65: 4500-5.
186. von Bubnoff N, Manley PW, Mestan J, et al. Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). Blood 2006; 108: 1328-33.
187. Peng B, Hayes M, Resta D, et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 2004; 22: 935-42.
188. Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005; 44: 879-94.
189. Kantarjian H, Talpaz M, O'Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004; 103: 2873-8.
190. Kantarjian H, Pasquini R, Hamerschlak N, et al. Dasatinib or highdose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 2007; 109: 5143-50.
191. Ross DM, Branford S, Reynolds J, Koelmeyer R, Hughes TP. Molecular response at 6 months is a good early predictor of duration of treatment response in imatinib-treated chronic phase chronic myeloid leukaemia. Haematologica 2006; 91: 53-4 (Abstr 145).
192. Larson RA, Druker BJ, Guilhot F, et al. Correlation of pharmacokinetic data with cytogenetic and molecular response in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib - an analysis of IRIS study data. Blood 2006; 108: 131a (Abstr).
193. Picard S, Titier K, Etienne G, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007; 109: 3496-9.
194. White D, Saunders V, Grigg A, et al. Measurement of in vivo BCRABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia. J Clin Oncol 2007; 25: 4445-51.
195. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006; 108: 1809-20.